The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

149 Pension Fund, GSK had been in possession of a 1982 report by a GSK scientist who found that the ranitidine, which is the name of Zantac's chemical compound, interacts with nitrites found in ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...

Donald Trump is expected to confirm that the UK will not escape the pain of levies he claims will restore 'fairness' in ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...